As of 2024-12-14, the Relative Valuation of Intra-Cellular Therapies Inc (ITCI) is (19.92) USD. This relative valuation is based on P/E multiples. With the latest stock price at 83.03 USD, the upside of Intra-Cellular Therapies Inc based on Relative Valuation is -124.0%.
The range of the Relative Valuation is (14.13) - (22.09) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 17.3x - 27.1x | 24.0x |
| Forward P/E multiples | 17.3x - 27.5x | 24.9x |
| Fair Price | (14.13) - (22.09) | (19.92) |
| Upside | -117.0% - -126.6% | -124.0% |
| Date | P/E |
| 2024-12-12 | -102.37 |
| 2024-12-11 | -102.96 |
| 2024-12-10 | -102.02 |
| 2024-12-09 | -104.29 |
| 2024-12-06 | -103.79 |
| 2024-12-05 | -103.22 |
| 2024-12-04 | -105.50 |
| 2024-12-03 | -104.72 |
| 2024-12-02 | -105.60 |
| 2024-11-29 | -105.14 |
| 2024-11-27 | -106.29 |
| 2024-11-26 | -106.09 |
| 2024-11-25 | -104.33 |
| 2024-11-22 | -105.19 |
| 2024-11-21 | -104.89 |
| 2024-11-20 | -105.12 |
| 2024-11-19 | -102.31 |
| 2024-11-18 | -101.23 |
| 2024-11-15 | -102.40 |
| 2024-11-14 | -107.57 |
| 2024-11-13 | -108.29 |
| 2024-11-12 | -108.62 |
| 2024-11-11 | -112.40 |
| 2024-11-08 | -112.06 |
| 2024-11-07 | -111.10 |
| 2024-11-06 | -109.79 |
| 2024-11-05 | -109.54 |
| 2024-11-04 | -105.77 |
| 2024-11-01 | -106.23 |
| 2024-10-31 | -104.03 |
| 2024-10-30 | -104.92 |
| 2024-10-29 | -94.21 |
| 2024-10-28 | -94.30 |
| 2024-10-25 | -93.06 |
| 2024-10-24 | -92.85 |
| 2024-10-23 | -92.09 |
| 2024-10-22 | -94.63 |
| 2024-10-21 | -94.41 |
| 2024-10-18 | -96.16 |
| 2024-10-17 | -96.58 |
| 2024-10-16 | -93.40 |
| 2024-10-15 | -91.71 |
| 2024-10-14 | -90.64 |
| 2024-10-11 | -93.00 |
| 2024-10-10 | -90.36 |
| 2024-10-09 | -89.90 |
| 2024-10-08 | -88.86 |
| 2024-10-07 | -87.39 |
| 2024-10-04 | -89.47 |
| 2024-10-03 | -88.69 |